AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01664026 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based lifestyle modification +
Description: Access to a web-based lifestyle modification program of 6-month duration that covers all aspects of a healthy lifestyle including physical activity, nutrition and weight maintenance plus telephone counseling support by health coaches on a weekly or bi-weekly basis.
Study NCT03820492 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: OCT, FFR, CTA and FFRCT
Description: Multimodality assessment of intermediate left main stenosis: Comparison of optical coherence tomography-derived minimal lumen area, invasive fractional flow reserve and FFRCT
Study NCT02522819 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP
Description: Use of CPAP over 5 nights for the treatment of obstructive sleep apnea in the acute phase of stroke.
Study NCT00460928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous immune globulin (IVIG)
Study NCT00318955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Study NCT00318955 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Study NCT02371629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVA237
Description: NVA237 capsules for inhalation, delivered via a Single Dose Dry Powder Inhaler (SDDPI) called Concept1
Study NCT02371629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to NVA237
Study NCT02371629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol
Description: All patients received salbutamol (100 μg) as only rescue medication
Study NCT00551707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRx-102 (2.7/180)
Description: prednisolone 2.7 mg plus dipyridamole 180 mg
Study NCT00551707 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisolone
Description: prednisolone (2.7 mg)
Study NCT00551707 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dipyridamole
Description: dipyridamole 360 mg
Study NCT00551707 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT00551707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRx-102 (2.7/360)
Description: Prednisolone 2.7 mg plus Dipyridamole 360 mg
Study NCT03497299 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active rTMS (20Hz)
Description: Repetitive Transcranial Magnetic Stimulation (rTMS) Procedures: On Day 1, participants will be randomly assigned to receive active or sham rTMS using the MagProX100/R30 stimulator equipped with the B65 active/ placebo coil for DLPFC stimulator (MagVenture, Farum, Denmark) for a period of 28 days.
Study NCT03497299 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham rTMS
Description: Repetitive Transcranial Magnetic Stimulation (rTMS) Procedures: On Day 1, participants will be randomly assigned to receive active or sham rTMS using the MagProX100/R30 stimulator equipped with the B65 active/ placebo coil for DLPFC stimulator (MagVenture, Farum, Denmark) for a period of 28 days.
Study NCT05241587 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gum Group:
Description: Gum Group:~Gum group patients consisted of patients who chewed Xylitol Granule Filled Dragee Sugar Free Gum/Xylitol Gum/First X-Fresh. It is reported that the use of xylitol five times a day (not less than three times) is appropriate and effective (Xylitol, 2020; Xylitol, 2006; Llop, et al., 2010).
Study NCT05241587 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mouth Spray Group:
Description: Mouth Spray Group:~The patients in the mouth spray group included those who had been using Oral Spray/Act Dry Mouth Spray regularly as two puffs three times a day at the request of the physician for the last two weeks. This group of patients continued to use the mouth spray at the physician's request.
Study NCT04833036 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: 180 mg/m2, ivgtt d1，q2w
Study NCT02323061 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: BCI using EEG signals
Description: A robot hand will be used and controlled by the system in real time based on EEG pattern for identification of motion intention for hand movements in the cortex.
Study NCT01594268 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Everolimus
Description: A prospective, open-label study to assess safety of Certican in kidney transplant patients
Study NCT03195530 — intervention group
Intervention type: DRUG
Intervention: Propofol
Description: Induction of anesthesia using propofol, and recording the BIS values and EEG patterns during the induction
Study NCT03055195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepolizumab 100 mg
Description: Mepolizumab is available as lyophilized powder in sterile vials for injection. The content is reconstituted with 1.2 milliliter (mL) Sterile Water just prior to use. Subjects will receive 1mL (100 mg/mL) bolus subcutaneous injections.
Study NCT03055195 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching mepolizumab
Description: Placebo is available as 0.9% sodium chloride solution. Subjects will receive 1mL bolus subcutaneous injections.
Study NCT02375997 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Palliative care
Description: Early nutrition intervention and psychological intervention
Study NCT01665378 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multiple Micronutrient
Description: There is no current recommendation for weekly MM supplements for WRA. Therefore, we propose a supplement that contains: The same amounts of iron and folic acid as the weekly, pre-natal IFA supplement; An amount of vitamin D based on the Food and Nutrition Board's Recommended Daily Allowances (RDA); UNICEF/WHO/UNU recommended amounts of remaining nutrients (UNIMMAP recommendations). The supplement is taken weekly during pre-pregnancy.~Vitamin A (μg) 800 Vitamin D (IU) 600 Vitamin E (mg) 10 Vitamin C (mg) 70 Thiamine (mg) 1.4 Riboflavin (mg) 1.4 Niacin (mg) 18 Vitamin B6 (mg) 1.9 Vitamin B12 (μg) 2.6 Folic acid (μg)\* 2800 Iron (mg)\* 60 Zinc (mg) 15 Copper (mg) 2 Selenium (μg) 65 Iodine (μg) 150
Study NCT01665378 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Iron and Folic Acid
Description: The doses of weekly and daily iron (60mg) and folic acid (2800μg) are based on current WHO recommendations for WRA.
Study NCT01665378 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Folic Acid
Description: It is unethical to have a placebo group as FA is universally recommended for WRA to prevent neural tube defects. Therefore, the control group will receive 2800 μg FA once a week during the pre-pregnancy period. This dosage is safe and meets the minimum recommended intake of 400 μg/d for Women of Reproductive Age (WRA). Recent studies have shown that a weekly dose of 2800 μg FA is as effective as a daily dose of 400 μg in improving folic acid and reducing homocysteine levels among WRA.
Study NCT01794975 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Study NCT01794975 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atomoxetine
Study NCT01794975 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cold pressor test
Study NCT01794975 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study NCT01794975 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03033043 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Relay Pro Stent-Graft
Description: Endovascular treatment of an aortic dissection
Study NCT02952677 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Remind-to-move
Description: Participants were required to wear sensory cueing wristwatch devices with vibration emitted on the affected arm for 3 consecutive hours daily, for a total of 4 weeks, at any time during the day, and received usual care as well.
Study NCT02952677 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Participants were required to wear sensory cueing wristwatch devices without vibration emitted on the affected arm for 3 consecutive hours daily, for a total of 4 weeks, at any time during the day, and received usual care as well.
Study NCT02952677 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Participants received usual care
Study NCT02952677 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Participants received usual care
Study NCT02952677 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Participants received usual care
Study NCT00677287 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RNF43, TOMM34, VEGFR1 and VEGFR2
Description: Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, RNF43 peptide (1mg), TOMM34 peptide (1mg), VEGFR1 peptide (1mg) and VEGFR2 peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection in combination with Tegafur/Uracil/Folinate chemotherapy.
Study NCT05003999 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HPC - SpeediCath ®
Description: The investigators measure the time taken to perform intermittent catheterization using a 13 step pre-determined intermittent catheterization protocol using a hydrophilic catheter
Study NCT05003999 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-HPC - Self-Cath ®
Description: The investigators measure the time taken to perform intermittent catheterization using a 13 step pre-determined intermittent catheterization protocol using a non-hydrophilic catheter; Lubrication jelly (MUKO ®, 3.5g package, Cardinal Health Canada Inc, Toronto, ON, Canada) was provided
Study NCT02550210 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Breast Cancer Locator (BCL)
Description: This locator is constructed pre-operatively, sterilized and provided to the surgeon at the time of the procedure. The outline of the breast cancer on the breast surface at the point where the cancer is closest to the skin is built into the locator, so that the surgeon can simply apply the locator to the patient's breast and trace the tumor outline on the skin.
Study NCT00924482 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Placed ECOM endotracheal cardiac output monitor in patients undergoing cardiac surgery
Description: Measure cardiac output during perioperative period and compare to pulmonary artery thermodilution cardiac output measurements.
Study NCT01027416 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen
Description: Drug: Tamoxifen 20 mg orally 1x/day for 4 weeks
Study NCT00396669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: We measure dopamine release at the striatum using 11 C Raclopride at baseline and after smoking a cigarette
Study NCT00396669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: Brain imaging after treatment with Bupropion
Study NCT00899275 — intervention group
Intervention type: OTHER
Intervention: Cytology Specimen Collection Procedure
Description: Correlative studies
Study NCT02912377 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Neulasta, B12019
Description: GCSF, Growth Colony Stimulating Factor
Study NCT00226733 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Interval exercise training with high intensity five days per week for four weeks.
Study NCT00226733 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise training
Description: Exercise training with moderate intensity, five days per week for four weeks.
Study NCT01056575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OC000459
Description: OC000459 100mg tablet, twice daily
Study NCT00477724 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: exercise and respiratory therapy
Description: exercise and respiratory therapy for three weeks in-hospital and 15 weeks at home
Study NCT00477724 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: sedentary control group
Description: control group with no specific training
Study NCT00999206 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Vaccine
Description: surface antigen, inactivated, prepared in cell cultures
Study NCT00999206 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza Vaccine
Description: surface antigen, inactivated, prepared in egg (influvac ®)
Study NCT00770484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol then Placebo
Description: Propanolol 20 mg, given orally within 1 hour prior to exercising
Study NCT00770484 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo then Propranolol
Description: Placebo, matching pill given orally within 1 hour prior to exercising
Study NCT03687255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cefepime/AAI101 combination
Description: cefepime 2 g / AAI101 500 mg
Study NCT03687255 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Piperacillin/tazobactam
Description: piperacillin 4 GM / tazobactam 500 MG
Study NCT02866383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 3 mg/kg is given over 60 minutes I.V. on day 1 just after radiation and then every 2 weeks (q2w)
Study NCT02866383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: 1 mg/kg is given over 90 minutes I.V. on day 1 30 minutes after the completion of nivolumab infusion and then every 6 weeks IV (q6w)
Study NCT02866383 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 15 Gy x 1 fraction given on day 1
Study NCT03083041 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SHR-1210
Description: SHR-1210 will be administered as a 30-minute IV infusion Q2W at a dose of 200mg
Study NCT03083041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib tablet will be administered orally,once daily until progression
Study NCT04833036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 180 mg/m2, ivgtt d1，q2w
Study NCT04833036 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cetuximab
Description: 500 mg/m2, ivgtt d1，q2w
Study NCT04833036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: 500 mg/m2, ivgtt d1，q2w
Study NCT03880812 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Societal cost
Description: Annual societal cost information to the US for carpal tunnel release surgery was displayed.
Study NCT01663649 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Deprexis
Description: web-based treatment program for depression
Study NCT01663649 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Deprexis
Description: web-based treatment program for depression
Study NCT01663649 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Wait-list
Description: the wait-list group receives Deprexis after 6 month
Study NCT03406962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGTA-456
Description: Hematopoietic stem cell transplantation will be done with the cell therapy product MGTA-456.
Study NCT02704104 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AC5 Topical Hemostatic Device
Description: Randomized application of the hemostatic agent AC5 to one of two freshly excised lesions in each patient
Study NCT02704104 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: AC5 Topical Hemostatic Device
Description: Randomized application of the hemostatic agent AC5 to one of two freshly excised lesions in each patient
Study NCT00824421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UK-453, 061
Description: UK-453,061 500 mg tablets PO QD + Tenofovir DF 300 mg/Emtricitabine 200 mg tablets PO QD.
Study NCT00824421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UK-453, 061
Description: UK-453,061 750 mg tablets PO QD + Tenofovir DF 300 mg/Emtricitabine 200 mg tablets PO QD.
Study NCT00824421 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EFV +TVA
Description: Efavirenz 600 mg tablets PO QD + Tenofovir DF 300 mg/Emtricitabine 200 tablets mg PO QD.
Study NCT00983775 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: jet injector (SQ pen/Novopen III)
Description: The rapid-acting insulin analogue insulin aspart (Novorapid®), at a dose of 0.2 units per kg body weight, will be injected subcutaneously. On one experimental day insulin will be injected with the jet injector and placebo with the conventional insulin pen. On the other experimental day insulin will be injected with the conventional insulin pen and placebo with the jet injector.
Study NCT00983775 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: jet injector (SQ pen/Novopen III)
Description: The rapid-acting insulin analogue insulin aspart (Novorapid®), at a dose of 0.4 units per kg body weight, will be injected subcutaneously. On one experimental day insulin will be injected with the jet injector and placebo with the conventional insulin pen. On the other experimental day insulin will be injected with the conventional insulin pen and placebo with the jet injector.
Study NCT02499952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200mg IV every 3 weeks until progressive disease, unacceptable toxicity, or after 52 weeks of therapy.
Study NCT00350220 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: transfusion strategy
Description: For the High Hb group; transfusions will be given to keep the Hb >13.0 g/dl
Study NCT00350220 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low Hb transfusion group
Description: RBCs will not be transfused unless the Hb \< 9.0 g/dl
Study NCT02950584 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Titanium dioxide denture
Description: Patients will receive titanium dioxide denture (made from acrylic resin with titanium dioxide nanoparticles) for 1 month in the initial phase then in the second phase after one month they will receive (rapid heat cured acrylic resin)denture according to the principle of crossover design
Study NCT02950584 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Titanium dioxide denture
Description: Patients will receive titanium dioxide denture (made from acrylic resin with titanium dioxide nanoparticles) for 1 month in the initial phase then in the second phase after one month they will receive (rapid heat cured acrylic resin)denture according to the principle of crossover design
Study NCT02950584 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Rapid heat denture
Description: Patients will receive rapid heat denture for 1 month in the initial phase of the trial then in the later phase patients will receive titanium dioxide denture (made from conventional acrylic resin modified by titanium dioxide nanoparticles) according to the principle of crossover design
Study NCT02950584 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rapid heat denture
Description: Patients will receive rapid heat denture for 1 month in the initial phase of the trial then in the later phase patients will receive titanium dioxide denture (made from conventional acrylic resin modified by titanium dioxide nanoparticles) according to the principle of crossover design
Study NCT02595710 — intervention group
Intervention type: OTHER
Intervention: skin punch biopsy collection
Description: Four-mm skin biopsies from non-lesional skin will be acquired from the patients, processed using our published techniques with Bartonella biomarkers, and imaged using confocal microscopy.
Study NCT02595710 — intervention group
Intervention type: OTHER
Intervention: Blood collection
Description: Blood will be tested for presence of Bartonella DNA and Bartonella antibodies using the Alpha Proteobacterium Growth Medium (BAPGM) multi-platform testing, including liquid culture, enriched agar plating and molecular techniques.Blood smears will be analyzed for presence of intra-erythrocytic Bartonella spp. by immunostaining.
Study NCT02595710 — intervention group
Intervention type: OTHER
Intervention: Urine sample collection
Description: Urine samples will be collected and analyzed for Bartonella spp specific microRNAs.
Study NCT03560596 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adherence Intervention
Description: 9 sessions with bilingual health coaches who will utilize a culturally tailored adherence checklist to identify patients specific medication adherence barriers.
Study NCT03560596 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: standard hypertension treatment recommendations as determined by PCP
Study NCT02565472 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White grape juice
Study NCT02565472 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Apple juice
Study NCT01442636 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: stent
Description: Implantation of one or more Everolimus-eluting XIENCE PRIME™ Everolimus Eluting Coronary Stent Systems.
Study NCT04548128 — intervention group
Intervention type: DEVICE
Intervention: HeartMate 3 Left Ventricular Assist System (HM3 LVAS)
Description: This clinical trial investigates implant of the HM3 LVAS by techniques other than full median sternotomy.
Study NCT04504760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-2910
Description: Single ascending dose of ONO-2910 will be administered orally.